CLAI Stock Overview
Engages in the manufacture and sale of biosynthetic cannabinoids-based consumer products in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cel AI PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.00052 |
| 52 Week High | UK£0.008 |
| 52 Week Low | UK£0.0005 |
| Beta | -1.51 |
| 11 Month Change | -19.23% |
| 3 Month Change | -41.67% |
| 1 Year Change | -88.33% |
| 33 Year Change | -99.42% |
| 5 Year Change | n/a |
| Change since IPO | -99.72% |
Recent News & Updates
Shareholder Returns
| CLAI | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 1.7% |
| 1Y | -88.3% | 20.7% | 8.4% |
Return vs Industry: CLAI underperformed the UK Personal Products industry which returned 20.7% over the past year.
Return vs Market: CLAI underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| CLAI volatility | |
|---|---|
| CLAI Average Weekly Movement | 8.6% |
| Personal Products Industry Average Movement | 4.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CLAI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: CLAI's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 5 | Mike Edwards | www.getcel.ai |
Cel AI PLC, together with its subsidiaries, engages in the manufacture and sale of biosynthetic cannabinoids-based consumer products in the United Kingdom. The company provides cannabinoid solutions for skincare and ingestible products. It offers its products through retailers; direct to consumers through its website; and online.
Cel AI PLC Fundamentals Summary
| CLAI fundamental statistics | |
|---|---|
| Market cap | UK£316.18k |
| Earnings (TTM) | -UK£2.11m |
| Revenue (TTM) | UK£54.16k |
5.8x
P/S Ratio-0.1x
P/E RatioIs CLAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLAI income statement (TTM) | |
|---|---|
| Revenue | UK£54.16k |
| Cost of Revenue | UK£20.15k |
| Gross Profit | UK£34.01k |
| Other Expenses | UK£2.14m |
| Earnings | -UK£2.11m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0035 |
| Gross Margin | 62.80% |
| Net Profit Margin | -3,892.32% |
| Debt/Equity Ratio | 0% |
How did CLAI perform over the long term?
See historical performance and comparison